Bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting VEGF-A, has been approved by the U.S. Food and Drug Administration as a treatment for ovarian cancer [46, 47]. Here, VEGFA is linked to ovarian carcinoma.